Related Experiment Video
Updated: Aug 11, 2026
08:41
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Clinical pharmacokinetics of docetaxel : recent developments
Sharyn D Baker1, Alex Sparreboom, Jaap Verweij
1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000, USA. sbaker7@jhmi.edu
Clinical Pharmacokinetics
|March 3, 2006
Summary
Docetaxel, a taxane chemotherapy, treats various cancers by stabilizing microtubules. Its complex metabolism and elimination by CYP3A enzymes and P-glycoprotein cause significant patient variability.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Docetaxel is a taxane antineoplastic agent effective against various cancers, including breast and lung cancer.
- Its mechanism involves inducing microtubular stability, disrupting cellular division.
Purpose of the Study:
- To investigate the complex pharmacokinetics and metabolism of docetaxel.
- To understand the factors contributing to interindividual variability in docetaxel handling.
Main Methods:
- Review of existing literature on docetaxel pharmacokinetics and metabolism.
- Analysis of docetaxel's interaction with cytochrome P450 (CYP) 3A isoenzymes.
- Examination of docetaxel's elimination pathways involving drug-transporting proteins like P-glycoprotein.
Main Results:
- Docetaxel undergoes extensive metabolism by CYP3A isoenzymes into inactive products.
- Drug elimination is influenced by P-glycoprotein, affecting drug handling.
- Significant interindividual variability in docetaxel pharmacokinetics exists due to these processes.
Conclusions:
- Docetaxel's complex metabolism and elimination contribute to variable patient responses.
- Individualized dosing strategies based on CYP3A variations may optimize chemotherapy.
- Further research into docetaxel pharmacogenetics can enhance its therapeutic efficacy.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:10Pharmacokinetics: Overview
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:21Toxicokinetics: Overview
Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...